omniture
苏州宜联生物医药有限公司 MediLink Therapeutics

Latest News

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), ...

2024-10-08 08:00 1339

MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits

* The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024...

2024-09-14 01:00 2983

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

SUZHOU, China, May 26, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), ...

2024-05-27 08:00 1316

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology

SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today tha...

2024-01-02 22:00 1740

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate

SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today th...

2023-10-12 19:00 1723

MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment

----- YL201 Phase I/II Investigators Meeting was successfully held in Guangzhou, China GUANGZHOU, ...

2023-09-23 18:29 2588

MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product

SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first...

2022-04-12 20:55 671

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) re...

2022-03-14 20:50 2236

Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global...

2021-03-01 19:50 4723